X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs AUROBINDO PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES AUROBINDO PHARMA DIVIS LABORATORIES/
AUROBINDO PHARMA
 
P/E (TTM) x 31.8 18.5 171.9% View Chart
P/BV x 7.0 3.7 192.2% View Chart
Dividend Yield % 0.6 0.3 186.4%  

Financials

 DIVIS LABORATORIES   AUROBINDO PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
AUROBINDO PHARMA
Mar-18
DIVIS LABORATORIES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,142809 141.1%   
Low Rs533504 105.8%   
Sales per share (Unadj.) Rs146.6281.1 52.2%  
Earnings per share (Unadj.) Rs33.041.4 79.9%  
Cash flow per share (Unadj.) Rs38.450.9 75.5%  
Dividends per share (Unadj.) Rs10.002.50 400.0%  
Dividend yield (eoy) %1.20.4 313.6%  
Book value per share (Unadj.) Rs222.8199.4 111.8%  
Shares outstanding (eoy) m265.47585.88 45.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.72.3 244.6%   
Avg P/E ratio x25.315.9 159.7%  
P/CF ratio (eoy) x21.812.9 169.0%  
Price / Book Value ratio x3.83.3 114.1%  
Dividend payout %30.36.0 500.7%   
Avg Mkt Cap Rs m222,318384,630 57.8%   
No. of employees `00010.817.3 62.1%   
Total wages/salary Rs m4,56121,308 21.4%   
Avg. sales/employee Rs Th3,616.09,500.7 38.1%   
Avg. wages/employee Rs Th423.81,229.4 34.5%   
Avg. net profit/employee Rs Th814.91,397.9 58.3%   
INCOME DATA
Net Sales Rs m38,915164,666 23.6%  
Other income Rs m1,1341,020 111.2%   
Total revenues Rs m40,049165,686 24.2%   
Gross profit Rs m12,61737,718 33.5%  
Depreciation Rs m1,4255,580 25.5%   
Interest Rs m13777 1.7%   
Profit before tax Rs m12,31332,380 38.0%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,5438,183 43.3%   
Profit after tax Rs m8,77024,229 36.2%  
Gross profit margin %32.422.9 141.5%  
Effective tax rate %28.825.3 113.9%   
Net profit margin %22.514.7 153.2%  
BALANCE SHEET DATA
Current assets Rs m45,351121,878 37.2%   
Current liabilities Rs m6,50786,806 7.5%   
Net working cap to sales %99.821.3 468.6%  
Current ratio x7.01.4 496.4%  
Inventory Days Days127130 97.6%  
Debtors Days Days9568 139.2%  
Net fixed assets Rs m21,16081,037 26.1%   
Share capital Rs m531586 90.6%   
"Free" reserves Rs m58,625116,218 50.4%   
Net worth Rs m59,156116,804 50.6%   
Long term debt Rs m04,512 0.0%   
Total assets Rs m67,832211,052 32.1%  
Interest coverage x926.842.7 2,172.4%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.8 73.5%   
Return on assets %12.911.8 109.3%  
Return on equity %14.820.7 71.5%  
Return on capital %20.827.4 76.2%  
Exports to sales %00-   
Imports to sales %21.80-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,35980,727 40.1%   
Fx outflow Rs m9,04234,700 26.1%   
Net fx Rs m23,31746,027 50.7%   
CASH FLOW
From Operations Rs m7,75919,548 39.7%  
From Investments Rs m-4,783-19,570 24.4%  
From Financial Activity Rs m-3,1428,642 -36.4%  
Net Cashflow Rs m-1668,922 -1.9%  

Share Holding

Indian Promoters % 52.0 54.1 96.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 8.0 148.4%  
FIIs % 19.0 27.7 68.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 10.2 168.6%  
Shareholders   31,796 69,601 45.7%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   FDC LTD.  UNICHEM LAB  WYETH LTD  AJANTA PHARMA  ALEMBIC LTD  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Recapitalisation Package for PSBs: The Pros & Cons(Podcast)

Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 22, 2019 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - ABBOTT INDIA COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS